These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 30947564)

  • 1. Human Biofield Therapy and the Growth of Mouse Lung Carcinoma.
    Yang P; Jiang Y; Rhea PR; Coway T; Chen D; Gagea M; Harribance SL; Cohen L
    Integr Cancer Ther; 2019; 18():1534735419840797. PubMed ID: 30947564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Biofield Therapy Modulates Tumor Microenvironment and Cancer Stemness in Mouse Lung Carcinoma.
    Yang P; Rhea PR; Conway T; Nookala S; Hegde V; Gagea M; Ajami NJ; Harribance SL; Ochoa J; Sastry JK; Cohen L
    Integr Cancer Ther; 2020; 19():1534735420940398. PubMed ID: 32975128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
    Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional Heterogeneity of CD4
    Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
    Front Immunol; 2018; 9():2654. PubMed ID: 30505306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.
    Lou Y; Diao L; Cuentas ER; Denning WL; Chen L; Fan YH; Byers LA; Wang J; Papadimitrakopoulou VA; Behrens C; Rodriguez JC; Hwu P; Wistuba II; Heymach JV; Gibbons DL
    Clin Cancer Res; 2016 Jul; 22(14):3630-42. PubMed ID: 26851185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
    Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
    Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of CD4+ CD25+ regulatory T-cells detection in tumor-draining lymph nodes of nonsmall cell lung cancer patients].
    Su YJ; Ren K; Li H; Ren XB; Wang CL
    Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):922-6. PubMed ID: 18478932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
    Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen.
    Wang LJ; Li J; Hao FR; Yuan Y; Li JY; Lu W; Zhou TY
    Acta Pharmacol Sin; 2016 Jun; 37(6):845-56. PubMed ID: 27133297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multi-channel promotion of lung cancer progress by bone marrow derived mesenchymal stem cells in tumor microenvironment].
    Luo D; Hu SY; Liu GX
    Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):85-91. PubMed ID: 29502366
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
    Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
    Lopci E; Toschi L; Grizzi F; Rahal D; Olivari L; Castino GF; Marchetti S; Cortese N; Qehajaj D; Pistillo D; Alloisio M; Roncalli M; Allavena P; Santoro A; Marchesi F; Chiti A
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1954-61. PubMed ID: 27251642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
    Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
    J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
    Lo Russo G; Moro M; Sommariva M; Cancila V; Boeri M; Centonze G; Ferro S; Ganzinelli M; Gasparini P; Huber V; Milione M; Porcu L; Proto C; Pruneri G; Signorelli D; Sangaletti S; Sfondrini L; Storti C; Tassi E; Bardelli A; Marsoni S; Torri V; Tripodo C; Colombo MP; Anichini A; Rivoltini L; Balsari A; Sozzi G; Garassino MC
    Clin Cancer Res; 2019 Feb; 25(3):989-999. PubMed ID: 30206165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer.
    Singhal S; Stadanlick J; Annunziata MJ; Rao AS; Bhojnagarwala PS; O'Brien S; Moon EK; Cantu E; Danet-Desnoyers G; Ra HJ; Litzky L; Akimova T; Beier UH; Hancock WW; Albelda SM; Eruslanov EB
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.